| 2933.49.08 | 00 | 4,7-Dichloroquinoline | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P) 0.2￠/kg + 3.1% (SG) | 15.4￠/kg + 52% |
| 2933.69.60 | 15 | Sodium dichloroisocyanurate and trichloroisocyanuric acid | kg | | | |
| 2933.99.12 | 00 | 6-Bromo-5-methyl-1H-imidazo[4,5-b]- pyridine; 2-sec-Butyl-4-tert-butyl-6-(benzotriazol-2- yl)phenol; 2-tert-Butyl-4-methyl-6-(5-chlorobenzotri- azol-2-yl)phenol; 2,4-Di-tert-butyl-6-(benzotriazol-2-yl)phenol; 2,4-Di-tert-butyl-6-(5-chlorobenzotriazol-2- yl)phenol; 2,3-Dichloro-6-quinoxalinecarbonyl chloride; 1-Hydroxy-2-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid, sodium salt; Iminodibenzyl(10,11-dihydro-5H-dibenz- [b,f]azepine); Indoline; 3-Methylbenzo[f]quinoline; 2-Methylindoline; 2-Methylmercaptobenzimidazole; 1-Methyl-2-phenylindole; 1-Methylpyrazine; 2,4-Methylpyrazolic acid; 2-Phenylbenzimidazole; 2-Phenylindole; Tetramethylpyrazine; 2,3,5-Triphenyltetrazolium chloride; dl-Tryptophan; and Vinylcarbazole, monomer | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2934.10.70 | 00 | 4,5-Dichloro-2-n-octyl-4-isothiazolin-3-one; Ethyl 2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetate; Ethyl 2-(2-aminothiazol-4-yl)-2- methoxyiminoacetate; 2-Methyl-4-isothiazolin- 3-one; 2-n-Octyl-4-isothiazolin-3-one; and Thiothiamine hydrochloride | kg | Free | | 30.5% |
| 2934.20.25 | 00 | 2-Amino-5,6-dichlorobenzothiazole; 2-(4-Aminophenyl)-6-methylbenzothiazole-7- sulfonic acid; 2-Amino-6-nitrobenzothiazole; and N,N-Dicyclohexyl-2-benzothiazolesulfenamide | kg | Free | | 15.4￠/kg + 52% |
| 2934.99.05 | 00 | 5-Amino-3-phenyl-1,2,4-thiadiazole (3-Phenyl-5-amino-1,2,4-thiadiazole); 2-Hydroxybenzoxazole (Benzoxazolone); 4-Phenylmorpholine; 1,9-Thianthrenedicarboxylic acid; and Thioxanthene-9-one (Thioxanthone) | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2934.99.11 | 00 | 2-tert-Butyl-4-(2,4-dichloro-5- isopropoxyphenyl)- 2-1,3,4- oxadiazolin-5-one; 3-Isopropyl-1H-2,1,3- benzothiadiazin-4-(3H)-one-2,2- dioxide (Bentazon); and O,O-Diethyl-S-[(6-chloro-2- oxobenzoxazolin-3-yl)methyl]￠/phosphorodithioate (Phosalone) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 40.5% |
| 2935.00.13 | 00 | (5-[2-Chloro-4-(trifluoromethyl)phenoxy]-￠/(methylsulfonyl)-2-nitrobenzamide) (Fomesafen); N-(2,6-Dichloro-3-methylphenyl)-5-amino-1,3,4- triazole-2-sulfonamide; 2,4-Dichloro-5-sulfamoylbenzoic acid; N-Ethyl-o-toluenesulfonamide; N-Ethyl-p-toluenesulfonamide; 7-(Hexadecylsulfonylamino)-1H-indole; Methyl 5-{[(4,6-dimethoxy-2-pyrimidinyl)amino]- carbonylaminosulfonyl}-3-chloro-1-methyl-1H- pyrazole-4-carboxylate (Halosulfuron methyl); and Mixtures of ortho- and para-toluene sulfonamides | kg | Free | | 15.4￠/kg + 57.5% |
| 2941.10.30 | 00 | Carfecillin, sodium; Cloxacillin, sodium; Dicloxacillin, sodium; Flucloxacillin (Floxacillin); and Oxacillin, sodium | kg | Free | | 15.4￠/kg + 45% |
| 3002.20.00 | 00 | Vaccines for human medicine | kg | Free | | Free |
| 3002.30.00 | 00 | Vaccines for veterinary medicine | kg | Free | | Free |
| 3003 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale: | | | | |
| 3004 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: | | | | |
| 3004.40.00 | 10 | Cardiovascular medicaments | kg | | | |
| 3004.40.00 | 20 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.40.00 | 60 | Medicaments primarily affecting the eyes, ears or respiratory system | kg | | | |
| 3004.50 | | Other medicaments containing vitamins or other products of heading 2936: | | | | |
| 3004.90.91 | 05 | Anti-infective medicaments: | | | | |
| 3004.90.91 | 15 | Antineoplastic and immunosuppressive medicaments | kg | | | |
| 3004.90.91 | 20 | Cardiovascular medicaments | kg | | | |
| 3004.90.91 | 22 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.90.91 | 50 | Medicaments primarily affecting the digestive system: | | | | |
| 3005 | | Wadding, gauze, bandages and similar articles (for example, dressings, adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packings for retail sale for medical, surgical, dental or veterinary purposes: | | | | |
| 3006.70.00 | 00 | Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | kg | 5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 25% |
| 3204.11.18 | 00 | N-[2-[(2,6-Dicyano-4-methylphenylazo]-5- (diethylamino)-phenyl] methanesulfonamide; and N-[2-[2,6-Dicyano-4-methylphenylazo]-5- (di-1-propylamino) phenyl]methanesulfon- amide | kg | Free | | 63.5% |
